Transfer Pricing Considerations for Life Sciences Companies Expanding Globally  

Global expansion is one of the most exciting milestones a life sciences company can hit. New markets, new clinical partnerships, access to talent pools and research ecosystems in Europe, Asia, or Latin America. The opportunities are real. But alongside those opportunities comes one of the most technically complex areas of international tax: transfer pricing. 

For life sciences companies in particular, transfer pricing is not a back-burner compliance issue. It is a strategic consideration that can determine how profitable your international operations actually are, and whether you stay on the right side of tax authorities in multiple jurisdictions simultaneously. 

What Is Transfer Pricing, and Why Does It Matter for Life Sciences? 

Transfer pricing refers to the prices set for transactions between related entities within the same corporate group. If your U.S. parent company licenses intellectual property to your newly formed European subsidiary, the price charged for that license, known as the transfer price, determines how income and costs are allocated between the two entities, and therefore how much tax is owed in each country. 

This matters for every industry, but it is particularly high-stakes in life sciences for a few reasons. First, the most valuable assets in a life sciences company are often intangible: patents, drug formulations, clinical data, proprietary manufacturing processes, and trade secrets. These are notoriously difficult to value, which creates both flexibility and risk in how they are priced for intercompany transactions. 

Second, life sciences companies frequently structure global operations around R&D centers, manufacturing hubs, and distribution entities across multiple countries. Each of these creates intercompany transactions, including services provided, products sold, and IP licensed, all of which require defensible transfer pricing. 

According to the OECD, transfer pricing disputes account for the largest share of international tax controversies globally, and the life sciences sector consistently ranks among the most audited industries. The IRS, HMRC, and tax authorities in Germany, Japan, and Australia have all intensified scrutiny of life sciences transfer pricing in recent years. 

The Arm’s Length Principle: Your Foundation 

Every transfer pricing framework, in the U.S. and internationally, is built on the arm’s length principle. This principle holds that transactions between related parties should be priced as if they were conducted between independent parties under comparable circumstances. 

In practice, applying this principle to life sciences assets is complex because truly comparable transactions between unrelated parties are rare. A novel drug compound or proprietary assay technology may have no direct market comparables, which is why life sciences transfer pricing often requires sophisticated valuation methodologies and detailed economic analysis. 

The primary methods used to determine arm’s length pricing include the Comparable Uncontrolled Price (CUP) method, the Cost Plus method, the Resale Price method, and profit-based methods like the Transactional Net Margin Method (TNMM) and the Profit Split method. The best method depends on the nature of the transaction and the availability of reliable comparables. 

Key Transactions That Require Transfer Pricing Attention 

IP Licensing Arrangements 

If your parent entity holds patents or regulatory data and licenses them to a foreign subsidiary for commercialization, you need a defensible royalty rate. Too low, and the IRS may argue you shifted income offshore inappropriately. Too high, and foreign tax authorities may challenge costs being loaded onto their jurisdiction. 

Life sciences companies need particular care here because IP valuations are often the subject of audit disputes. The Buy-In and Buy-Out rules under U.S. Treasury regulations govern how existing IP is valued when it is contributed to a cost-sharing arrangement with a foreign subsidiary. 

Contract Research and Manufacturing 

Many life sciences companies outsource early-stage research or manufacturing to related entities in lower-cost jurisdictions. The transfer pricing for these arrangements, usually structured as cost plus a markup, must reflect what an independent contract research organization or manufacturer would charge for similar services. 

Intercompany Loans 

When a parent company funds a foreign subsidiary through intercompany debt, the interest rate must reflect market rates for comparable borrowing arrangements. This is often overlooked by early-stage companies focused on equity, but it becomes an audit trigger as operations scale. 

Documentation Requirements 

Most major jurisdictions now follow the OECD’s three-tier documentation framework, which includes a Master File (providing an overview of the entire group’s global operations and transfer pricing policies), Local Files (documenting specific intercompany transactions in each country), and a Country-by-Country Report (for groups above revenue thresholds, showing income and taxes paid in each jurisdiction). 

In the United States, Section 482 of the Internal Revenue Code governs transfer pricing, and IRS penalties for inadequate documentation can be substantial. The standard transfer pricing penalty is 20% of the underpayment, rising to 40% for gross valuation misstatements, which can occur when the transfer price is more than 200% or less than 50% of the correct arm’s length price. 

Preparing this documentation is not a one-time exercise. As your business evolves, whether through new products, new subsidiaries, or new transactions, your transfer pricing policies and documentation need to evolve with it. 

Advance Pricing Agreements: Reducing Uncertainty 

One of the most effective tools for managing transfer pricing risk in life sciences is an Advance Pricing Agreement (APA). An APA is an agreement between a company and one or more tax authorities that specifies the transfer pricing methodology to be used for a defined set of transactions over a defined period. 

For life sciences companies with significant IP transactions or complex global structures, an APA provides certainty, reduces the risk of audit adjustments, and, in the case of bilateral APAs covering two countries, eliminates the risk of double taxation. The process is time-consuming and resource-intensive, but for companies with material intercompany transactions, it is often worth the investment. 

Building Transfer Pricing Into Your Expansion Strategy 

The biggest mistake life sciences companies make is treating transfer pricing as an afterthought. Too many companies try to document it after the fact, once operations are already running. This approach creates both compliance risk and financial inefficiency. 

The time to think about transfer pricing is before you establish a foreign entity, before you execute an IP license, and before you structure a cost-sharing arrangement. Getting the structure right from the start ensures that your international operations are both tax-efficient and audit-ready. 

This requires collaboration between your legal, finance, and tax teams, or the right outside advisors who understand how transfer pricing intersects with your business model. 

Escalon works with growing life sciences companies to navigate the financial and tax complexity of global expansion. Learn more about how we support the Life Sciences industry or explore our full range of  

Explore our Tax Operations services to see how we can support your international tax strategy. 

The Bottom Line 

Transfer pricing is one of the most consequential and most misunderstood aspects of global expansion for life sciences companies. The intangible nature of your most valuable assets, the complexity of your operational structures, and the intense regulatory scrutiny of your industry all make it essential to get this right. 

The companies that manage transfer pricing successfully treat it as a strategic function rather than a compliance checkbox. They build documentation frameworks early, align their legal and tax structures with their economic substance, and work with advisors who understand the specific challenges of life sciences. 

When you get it right, transfer pricing is not just a compliance exercise. It is a tool for structuring your global operations in the most efficient, defensible, and sustainable way possible.